Insmed’s iPlex Gets Updated User Fee Date Of Dec. 12
This article was originally published in The Pink Sheet Daily
Insmed's NDA for the growth therapy iPlex (mecasermin rinfibate) has an updated user fee date of Dec. 12, the firm announced Oct. 25
You may also be interested in...
Exclusivity discussions with Office of Orphan Products Development are ongoing, CEO Geoffrey Allan says Sept. 28; letter requests chemistry, manufacturing and controls data.
The company plans to launch the extreme short stature therapy in January with a 30-member sales force.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.